• English
    X

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.

    ​Maryland STOP Act​​

    Impacts

    The STOP Act (Statewide Targeted Overdose Prevention Act), effective July 1, 2022, requires certain organizations to provide naloxone, Narcan, or another opioid overdose reversal drug (OORD) to the people they serve. The Maryland Department of Health (MDH) is required to purchase and provide naloxone or another OORD for identified organizations.


    Jump to the impacts on:

    Background​

    The STOP Act began as an administration bill written by the Maryland Department of Health Center for Harm Reduction Services (MDH CHRS) and the Maryland Opioid Operational Command Center (OOCC)As HB408 and SB394, the STOP Act passed unanimously through both Maryland state legislature chambers. The STOP Act created a new law that went into effect on July 1, 2022, requiring certain organizations to provide naloxone or another OORD.

    ​Implementation of the STOP Act is being overseen by MDH CHRS in collaboration with the regulatory agencies of affected organizations. Mandates to offer OORDs are in effect while the Department is able to purchase and provide OORDs to affected organizations.

    Goals​​

    1. Increase the number of access points for naloxone in Maryland communities​
    2. Ensure access to naloxone in organizations caring for those at greatest risk of overdose
    3. Establish long-term budget allocation for naloxone at the state level
    4. Create opportunities for training, capacity building, and other harm reduction initiatives at identified organizations

    Justification​​

    • Providing naloxone to people most likely to experience or witness an overdose ensures the best chance of reducing overdose mortality.
    • MDH CHRS calculates naloxone saturation based on how much naloxone is distributed to high-risk groups.
    • Maryland data suggests that a recent period of abstinence, previous experience of nonfatal overdose, and experiencing homelessness are risk factors for overdose.
    • The distribution of naloxone in Maryland falls short of meeting the needs of those most at risk, despite great advancements in access.

    Overdose Resp​​onse Program

    MDH authorizes government agencies and community-based organizations to become Overdose Response Programs (ORPs), allowing them to provide overdose prevention education and dispense naloxone to the community. Learn how to become an Overdose Response Program.

    Identified Orga​​nizations


    Businesses​​​​​​​​​​

    Effective July 1, 2022
    The STOP Act improved liability protections for businesses and business owners that offer naloxone or other OORDs.
    A cause of action may n​ot arise against any business or business owner for any act or omission when the business or busi​ness owner in good faith makes OORDs available to the employees or patrons of the business along with the necessary paraphernalia for administration of the OORD to an individual under 13-3104 or 13-3106.
    ​​​​

    EMS Providers​

    Effective July 1, 2022
    The STOP Act authorizes Emergency Medical Services providers (EMTs, CRTs, and Paramedics) to dispense OORD to patients by changing Article-Education §13-516. Many EMS already dispense take-home OORD through the MIEMSS Naloxone Leave-Behind Pilot protocols.
    EMS providers may dispense naloxone or another OORD to:
    • Individuals who receive treatment for a nonfatal drug overdose
    • Individuals who are evaluated by a crisis evaluation team

    Homeless Services Programs

    By June 30, 2024
    The STOP Act requires homeless services programs to offer free naloxone or another OORD to individuals they serve.
    ​On or before June 30, 2024, a homeless services program that provides services to individuals who have a substance use disorder or an opioid use disorder or are at risk of experiencing a drug overdose shall have a protocol to offer opioid overdose reversal drugs approved by the federal Food and Drug Administration, free of charge, to those individuals who have an opioid use disorder or are at risk of experiencing a drug overdose when the individual receives services from the community services program.
    Homeless Services Programs must offer free naloxone (or another OORD) to:
    • Individuals who have an opioid use disorder
    • Individuals at risk of experiencing a drug overdose

    State and Local Co​​​rrectional Facilities

    By June 30, 2024
    State and local correctional facilities shall have a protocol to offer an opioid overdose reversal drug approved by the federal Food and Drug Administration, free of charge, to sentenced individuals who have an opioid use disorder or who are at risk of experiencing a drug overdose before the individual’s release.
    State and Local Correctional Facilities must offer free naloxone (or another OORD) to:
    • Sentenced individuals, before release, who either (1) have an opioid use disorder or (2) are at risk of experiencing a drug overdose

    Division of Paro​le and Probation​ (DPP)

    By June 30, 2024
    The Division of Parole and Probation shall have a protocol to offer an opioid overdose reversal drug approved by the federal Food and Drug Administration, free of charge, to individuals under supervision who have an opioid use disorder or are at risk of experiencing a drug overdose.
    DPP must offer free naloxone (or another OORD) to:
    • Individuals under supervision who either (1) have an opioid use disorder or (2) are at risk of experiencing a drug overdose

    Intensive Outpatient P​​rograms (IO​​Ps)

    By June 30, 2023
    Intensive Outpatient Treatment Programs (IOPs) must have protocols to offer an OORD, free of charge, to all individuals receiving services. No diagnosis or qualifying criteria apply.
    ​​On or before June 30, 2023, each opioid treatment program and each intensive outpatient treatment program shall have a protocol to offer an opioid overdose reversal drug approved by the federal Food and Drug Administration, free of charge, when an individual receives services from the opioid treatment ​program or intensive outpatient treatment program.
    IOPs must offer free naloxone (or another OORD) to:
    • Individuals receiving services

    Opioid Treatmen​t​​ Programs (OTPs)

    By June 30, 2023
    Opioid Treatment Programs (OTPs) must have protocols to offer an OORD, free of charge, to all individuals receiving services. No diagnosis or qualifying criteria apply.
    On or before June 30, 2023, each opioid treatment program and each intensive outpatient treatment program shall have a protocol to offer an opioid overdose reversal drug approved by the federal Food and Drug Administration, free of charge, when an individual receives services from the opioid treatment program or intensive outpatient treatment program.
    OTPs must offer free naloxone (or another OORD) to:
    • Individuals receiving services

    Hospitals​​

    By June 30, 2023
    Since January 1, 2018, Md. Article-Health General §19-310.3 has required Maryland hospitals to have protocols for discharging patients treated for drug overdose or those with Substance Use Disorder (SUD). The prescription of naloxone was previously an optional feature of these protocols. With the passage of the STOP Act, these hospital protocols must now include not simply prescribing OORDs, but offering OORDs directly, free of charge, to patients who were treated for SUD, OUD, or drug overdose. This change ensures that patients who want OORDs receive them directly in-hand prior to discharge; this will reduce missed opportunities that occur because of prohibitive copays or loss to follow-up when providers refer patients to pharmacies for OORDs.
    Hospitals must directly offer free naloxone (or another OORD) to:
    • ​Patients who receive treatment for a substance use disorder, opioid use disorder, or nonfatal drug overdose event.